– Presentations highlighting preclinical data supporting the combination of FTIs with KRAS^G12C Inhibitors and Tyrosine Kinase Inhibitors –

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. KURAa clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has accepted two abstracts for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Orlando dated April 14-19, 2023.

“We look forward to presenting preclinical data supporting the combination of farnesyltransferase inhibitors (FTIs) with KRAS^G12C Inhibitors and tyrosine kinase inhibitors at this year’s AACR Annual Meeting,” said Troy Wilson, Ph.D., JD, President and Chief Executive Officer of Kura Oncology Combination agents to prevent or delay the emergence of resistance to certain classes of targeted therapies. We have plans Recently announced FDA approval of a new drug investigational application for our next-generation farnesyltransferase inhibitor, KO-2806, which is designed to improve the potency, pharmacokinetic and physicochemical properties of previous FTI drug candidates, and we look forward to initiating our FIT-001 Phase 1 study of KO-2806 later this year.”

Session titles and information for the two abstracts are listed below and are now available on the AACR Online Trip Planner.

Combination of tipifarnib with KRAS^G12C Inhibitors to prevent adaptive resistance
Session Category/Title: Clinical Research Without Trials/Precise Molecular Subtyping and Therapeutic Development
Meeting Date and Time: Sunday, April 16, 2023; 1:30 p.m. – 5:00 p.m. ET
Location: Orange County Convention Center, Poster Section 43
Summary / Poster: 1079 / 23

Tipifarnib acts synergistically with TKIs in clear cell renal cell carcinoma models
Session Category / Title: Clinical Research…